CUBE vs RNAZ · P/E 25, rev $1.07B vs $5.1M cap
CubeSmart (CUBE) versus Transcode Therapeutics Inc (RNAZ) — a side-by-side from cached financials, not a winner call.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Transcode Therapeutics Inc (RNAZ) is a biotechnology company listed on NASDAQ.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
RNAZ does not have a complete income-statement cache yet.
CUBE currently screens at market cap $9.69B and trailing P/E 25.0. RNAZ currently screens at market cap $5.1M.
Not investment advice. Open the CUBE and RNAZ stock pages for the full models.
Not investment advice.